{"drugs":["Hydroxyprogesterone Caproate","Hylutin","Makena","Prodrox"],"mono":{"0":{"id":"292900-s-0","title":"Generic Names","mono":"Hydroxyprogesterone Caproate"},"1":{"id":"292900-s-1","title":"Dosing and Indications","sub":{"0":{"id":"292900-s-1-4","title":"Adult Dosing","mono":"<ul><li>safety and efficacy have only been demonstrated in women with a prior spontaneous singleton preterm birth<\/li><li>not to be used in women with multiple gestations or other risk factors for preterm birth<\/li><li><b>Preterm labor, singleton pregnancy; Prophylaxis:<\/b> 250 mg IM once weekly (every 7 days) starting between 16 weeks, 0 days and 20 weeks, 6 days of gestation; continue until week 37 (through 36 weeks, 6 days) of gestation or delivery<\/li><\/ul>"},"1":{"id":"292900-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>safety and effectiveness have not been demonstrated in pediatric patients younger than 16 years.<\/li><li>safety and efficacy have only been demonstrated in women with a prior spontaneous singleton preterm birth<\/li><li>not to be used in women with multiple gestations or other risk factors for preterm birth<\/li><\/ul>"},"3":{"id":"292900-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Preterm labor, singleton pregnancy; Prophylaxis<br\/><b>Non-FDA Labeled Indications<\/b><ul><li>Amenorrhea<\/li><li>Endometrial carcinoma<\/li><li>Estrogen measurement, Endogenous; Diagnosis<\/li><\/ul>"}}},"3":{"id":"292900-s-3","title":"Contraindications\/Warnings","sub":[{"id":"292900-s-3-9","title":"Contraindications","mono":"<ul><li>breast cancer or other estrogen or progestin-sensitive cancer, known, suspected, or history of<\/li><li>hepatic disease<\/li><li>hepatic tumors, benign or malignant<\/li><li>hypertension, uncontrolled<\/li><li>pregnancy-related cholestasis<\/li><li>thrombosis or thromboembolic disorder, current or past history<\/li><li>vaginal bleeding, undiagnosed, abnormal (not related to pregnancy<\/li><\/ul>"},{"id":"292900-s-3-10","title":"Precautions","mono":"<ul><li>allergic reactions, including angioedema; have been reported; discontinue if necessary<\/li><li>arterial or deep venous thrombotic or thromboembolic events may occur; discontinue use<\/li><li>depression; risk of exacerbation; discontinue if serious recurrence<\/li><li>decreased glucose tolerance may occur (including prediabetic women)<\/li><li>fluid retention may occur<\/li><li>hypertension may occur; discontinue if necessary<\/li><li>jaundice may occur; discontinue if necessary<\/li><li>report suspected adverse reactions to Ther-Rx Corporation at 1-877-567-7676 or US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch.<\/li><\/ul>"},{"id":"292900-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Hydroxyprogesterone: B (FDA)<\/li><li>Hydroxyprogesterone: D (AUS)<\/li><\/ul>"},{"id":"292900-s-3-12","title":"Breast Feeding","mono":"Hydroxyprogesterone: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"292900-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Injection site pain (34.8%), Injection site pruritus (5.8%), Injection site reaction (4.5%), Pruritus (7.7%), Swelling at injection site (17.1%), Urticaria (12.3%)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (2.3%), Nausea (5.8%)<\/li><\/ul><b>Serious<\/b><br\/><b>Hematologic:<\/b>Thromboembolic disorder<br\/>"},"6":{"id":"292900-s-6","title":"Drug Name Info","sub":{"0":{"id":"292900-s-6-17","title":"US Trade Names","mono":"<ul><li>Hylutin<\/li><li>Prodrox<\/li><li>Makena<\/li><\/ul>"},"2":{"id":"292900-s-6-19","title":"Class","mono":"<ul><li>Endocrine-Metabolic Agent<\/li><li>Progestin<\/li><\/ul>"},"3":{"id":"292900-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"292900-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"292900-s-7","title":"Mechanism Of Action","mono":"Hydroxyprogesterone caproate is a synthetic progestin. The mechanism by which it decreases the risk of recurrent preterm birth is unknown.<br\/>"},"8":{"id":"292900-s-8","title":"Pharmacokinetics","sub":[{"id":"292900-s-8-23","title":"Absorption","mono":"Tmax, IM: 4.6 days <br\/>"},{"id":"292900-s-8-24","title":"Distribution","mono":"Protein binding, albumin and corticosteroid binding globulins: extensive <br\/>"},{"id":"292900-s-8-25","title":"Metabolism","mono":"Hepatic: extensive via CYP3A4- and CYP3A5-mediated reduction, hydroxylation, and conjugation reactions <br\/>"},{"id":"292900-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: 50% (free steroids and conjugated metabolites)<\/li><li>Renal: 30% (free steroids and conjugated metabolites)<\/li><\/ul>"},{"id":"292900-s-8-27","title":"Elimination Half Life","mono":"7.8 days <br\/>"}]},"9":{"id":"292900-s-9","title":"Administration","mono":"<b>Intramuscular<\/b><br\/>administration by healthcare provider <br\/>"},"10":{"id":"292900-s-10","title":"Monitoring","mono":"<ul><li>delivery at or beyond 37 weeks gestation is indicative of efficacy<\/li><li>glucose tolerance in prediabetic and diabetic women<\/li><li>fluid retention in patients with conditions which may be adversely influenced (eg, preeclampsia, epilepsy, migraine, asthma, or cardiac or renal dysfunction)<\/li><li>signs and symptoms of depression in patients with a history of depression<\/li><\/ul>"},"11":{"id":"292900-s-11","title":"How Supplied","mono":"<b>Makena<\/b><br\/>Intramuscular Solution: 250 MG\/ML<br\/>"},"12":{"id":"292900-s-12","title":"Toxicology","sub":[{"id":"292900-s-12-31","title":"Clinical Effects","mono":"<b>PROGESTINS<\/b><br\/>OVERDOSE:  Rarely do acute ingestions result in obvious clinical manifestations.  CHRONIC: Most  adverse effects are related to chronic or high-dose therapy.  Headache, dizziness, irregular menses, mastalgia, bloating, depression, decreased libido, cholestatic jaundice, hepatitis, oligomenorrhea, amenorrhea and thromboembolism may occur with chronic therapy.<br\/>"},{"id":"292900-s-12-32","title":"Treatment","mono":"<b>PROGESTINS <\/b><br\/><ul><li>Support: Single acute overdoses will seldom result in toxicity.  Supportive treatment is adequate in most situations.<\/li><li>Decontamination: Gastric decontamination is probably only necessary after very large ingestions or with toxic coingestants; administer activated charcoal in these cases.<\/li><li>Monitoring of patient: CHRONIC TOXICITY: Discontinue medication and monitor for signs of toxicity and treat symptomatically.  Obtain a baseline CBC and hepatic and renal function tests in symptomatic patients.<\/li><\/ul>"},{"id":"292900-s-12-33","title":"Range of Toxicity","mono":"<b>PROGESTINS<\/b><br\/>Toxicity is unlikely following an acute overdose.  There are insufficient data reported in the literature to assess the range of toxicity in terms of mg\/kg ingested. <br\/>"}]},"13":{"id":"292900-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to immediately report signs\/symptoms of thrombotic or thromboembolic events (eg, DVT, stroke) or jaundice.<\/li><li>Drug may cause fluid retention, pruritus, urticaria, nausea, or diarrhea.<\/li><li>Advise patient with diabetes or prediabetes to report worsening glycemic control as drug may cause decreased glucose tolerance.<\/li><li>Counsel patient with a history of clinical depression that drug may cause a recurrence and to seek medical help.<\/li><li>Tell patient to report swelling, oozing of blood or fluid, or increasing pain at the injection site.<\/li><\/ul>"}}}